Aadi Bioscience, Inc. (AADI)

NASDAQ: AADI · IEX Real-Time Price · USD
2.120
-0.050 (-2.30%)
At close: Mar 18, 2024, 4:00 PM
2.110
-0.010 (-0.47%)
Pre-market: Mar 19, 2024, 4:00 AM EDT
-2.30%
Market Cap 52.05M
Revenue (ttm) 24.35M
Net Income (ttm) -65.77M
Shares Out 24.55M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 182,147
Open 2.160
Previous Close 2.170
Day's Range 2.100 - 2.170
52-Week Range 1.550 - 8.650
Beta 0.23
Analysts Buy
Price Target 5.00 (+135.85%)
Earnings Date Mar 13, 2024

About AADI

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 89
Stock Exchange NASDAQ
Ticker Symbol AADI
Full Company Profile

Financial Performance

In 2023, AADI's revenue was $24.35 million, an increase of 60.06% compared to the previous year's $15.22 million. Losses were -$65.77 million, 8.68% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AADI stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 135.85% from the latest price.

Price Target
$5.0
(135.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled...

1 day ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid...

5 days ago - PRNewsWire

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES , March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and co...

12 days ago - PRNewsWire

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

LOS ANGELES , March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-drive...

13 days ago - PRNewsWire

Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa

After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of respons...

17 days ago - PRNewsWire

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

LOS ANGELES , Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathw...

21 days ago - PRNewsWire

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations LOS ANGELES , Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a...

7 weeks ago - PRNewsWire

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

- New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- LOS ANGELES , Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceut...

2 months ago - PRNewsWire

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: DRRXKTRA
3 months ago - Benzinga

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in P...

3 months ago - PRNewsWire

Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update

PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected ...

4 months ago - PRNewsWire

Aadi Bioscience to Participate in Jefferies London Healthcare Conference

LOS ANGELES , Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...

4 months ago - PRNewsWire

Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, November 8, 2023 LOS ANGELES , Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company...

4 months ago - PRNewsWire

Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

Aadi initiates  Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC) LOS ANGELES , Oct. 19,...

5 months ago - PRNewsWire

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial te...

5 months ago - PRNewsWire

Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

LOS ANGELES , Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathwa...

5 months ago - PRNewsWire

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

LOS ANGELES , Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathwa...

5 months ago - PRNewsWire

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth a...

6 months ago - PRNewsWire

Aadi Bioscience to Participate at Upcoming Investor Conferences

LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined canc...

6 months ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to includ...

7 months ago - PRNewsWire

Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

Company to Host Conference Call and Webcast on Wednesday, August 9, 2023 LOS ANGELES , Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company f...

8 months ago - PRNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: FGENINGNSILKTHRX
8 months ago - Benzinga

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES , May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...

10 months ago - PRNewsWire

Aadi Bioscience to Participate in Upcoming Investor Events

LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetical...

10 months ago - PRNewsWire

Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 4...

11 months ago - PRNewsWire